Targeted radioiodine therapy of ovarian cancer via the sodium/iodide symporter (NIS)

[Objective] Ovarian cancer is the most lethal gynecological malignancy, but current treatments have not improved overall survival and recurrence rates. New therapies are needed and, in this context, we propose the use of the sodium/iodide symporter (NIS) that enables effective targeted Radioiodide t...

Descripción completa

Detalles Bibliográficos
Autores: Mirela Mielu, Lidia, Rodal-Bravo, Lucía, Diego-Hernández, Cristina, Varona, Sarai, Fajardo-Delgado, Dánae, Hortiguela, Rafael, Torres-Ruiz, Mónica, Cuesta, Isabel, Pallares, Pilar, Santisteban, Pilar, García-Jiménez, Custodia, Martín-Duque, Pilar, Vieja, Antonio de la
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/420186
Acceso en línea:http://hdl.handle.net/10261/420186
Access Level:acceso abierto
Palabra clave:Ovarian cancer treatment
Sodium iodide symporter
Radioiodine (RAI) therapy
Targeted therapy
Descripción
Sumario:[Objective] Ovarian cancer is the most lethal gynecological malignancy, but current treatments have not improved overall survival and recurrence rates. New therapies are needed and, in this context, we propose the use of the sodium/iodide symporter (NIS) that enables effective targeted Radioiodide therapy (RAI), as NIS is overexpressed in ovarian cancer.

Similares en LA Referencia